Training Program in Cancer Immunobiology

癌症免疫生物学培训计划

基本信息

  • 批准号:
    8727260
  • 负责人:
  • 金额:
    $ 37.46万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1994
  • 资助国家:
    美国
  • 起止时间:
    1994-05-27 至 2015-10-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The purpose of this training program is to produce independent scientists capable of translating recent advances in immunology into progress in cancer research. Support is requested for 10 trainees (7 postdoctoral fellows and 3 graduate students) per year. The curriculum for graduate students consists of coursework, a qualifying examination, and research leading to the public defense of an original thesis. A broad range of courses in cell biology, genetics, statistics, biochemistry, and molecular biology is required of all graduate students, and additional courses and research experience is provided in immunobiology, molecular immunology, immunopathoiogy, tumor immunology, and cancer biology. The Postdoctoral Program consists of focused laboratory research while maximizing exposure to broad issues of cancer research thus giving trainees experience in all aspects of the cancer problem: basic, translational, and clinical research, disease detection, management and prevention, and patient perspectives and issues. In addition, a special enrichment program consisting of guest lectures, seminars, meetings with prominent researchers, and attendance of scientific meetings is provided for trainees. The 26 training faculty are all members of both the University of Texas M.D. Anderson Cancer Center and the Graduate School of Biomedical Sciences and are drawn from the Departments of Immunology (13), Cancer Biology (1), Biochemistry and Molecular Biology (1), Experimental Therapeutics (2), Lymphoma (2), Melanoma Medical Oncology (3), Stem Cell Transplantation (1), Systems Biology (1), Urology (1), and Pediatrics (1). The faculty members have been selected as trainers because they have research expertise in at least one of the 5 areas covered by the training program (immunobiology, molecular immunology, immunopathoiogy, tumor immunology, cancer biology/carcinogenesis) and a sincere interest in graduate student and postdoctoral education. The graduate students and postdoctoral fellows must be U. S. citizens or permanent residents, hold a bachelor's degree or a Ph.D/M.D. from a recognized college or university, have an excellent record of academic achievement as an undergraduate or during graduate/medical school, and be committed to a research career in cancer immunobiology. Students may be supported by the training grant during years 2-5 of their graduate training. Postdocs will be supported for 2 years and possibly a third year if there is demonstrable progress and need. All of the laboratories are modern, fully equipped facilities within the University of Texas M. D. Anderson Cancer Center which is part of the Texas Medical Center, one of the world's largest centers for medical care, research, and education. RELEVANCE: The relationship of the immune system and cancer is a long-standing interest of basic and clinical scientists. The rapid progress in the field of immunology needs to be applied to understanding the immunobiology of cancer and then translated into new strategies for the therapy or prevention of disease. The purpose of this program is, therefore, to provide research training for graduate students and postdoctoral trainees in cancer immunobiology, thus providing the next generation of scientists that focus on this important health problem.
描述(由申请人提供):该培训计划的目的是培养能够将免疫学的最新进展转化为癌症研究进展的独立科学家。每年需要支助10名受训人员(7名博士后研究员和3名研究生)。研究生的课程包括课程作业、资格考试和导致原创论文公开辩护的研究。在细胞生物学,遗传学,统计学,生物化学和分子生物学广泛的课程是必需的所有研究生,并在免疫生物学,分子免疫学,免疫病理学,肿瘤免疫学和癌症生物学提供额外的课程和研究经验。博士后计划包括重点实验室研究,同时最大限度地暴露于癌症研究的广泛问题,从而使学员在癌症问题的各个方面的经验:基础,转化和临床研究,疾病检测,管理和预防,以及患者的观点和问题。此外,还为学员提供了一个特别的充实方案,包括客座讲座、研讨会、与著名研究人员的会议以及参加科学会议。26名培训教师都是得克萨斯大学医学博士。来自安德森癌症中心和生物医学科学研究生院的研究人员来自免疫学系(13)、癌症生物学系(1)、生物化学和分子生物学系(1)、实验治疗学系(2)、淋巴瘤系(2)、黑色素瘤医学肿瘤学系(3)、干细胞移植系(1)、系统生物学系(1)、泌尿学系(1)和儿科学系(1)。教师被选为培训师,因为他们在培训计划所涵盖的5个领域(免疫生物学,分子免疫学,免疫病理学,肿瘤免疫学,癌症生物学/致癌作用)中至少有一个领域具有研究专长,并且对研究生和博士后教育有着真诚的兴趣。研究生和博士后研究员必须是美国的。S.公民或永久居民,持有学士学位或博士学位/医学博士学位。来自公认的学院或大学,在本科或研究生院/医学院期间有优异的学术成就记录,并致力于癌症免疫生物学的研究事业。学生可以在研究生培训的第2-5年获得培训补助金。博士后将获得2年的支持,如果有明显的进展和需求,可能会获得第三年的支持。所有的实验室都是现代化的,设备齐全的设施在德克萨斯大学M。D.安德森癌症中心是德克萨斯医疗中心的一部分,德克萨斯医疗中心是世界上最大的医疗、研究和教育中心之一。 免疫系统和癌症的关系是基础和临床科学家长期以来的兴趣。免疫学领域的快速进展需要应用于理解癌症的免疫生物学,然后转化为治疗或预防疾病的新策略。因此,该计划的目的是为癌症免疫生物学的研究生和博士后学员提供研究培训,从而为关注这一重要健康问题的下一代科学家提供支持。

项目成果

期刊论文数量(82)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Sleeping beauty system to redirect T-cell specificity for human applications.
  • DOI:
    10.1097/cji.0b013e3182811ce9
  • 发表时间:
    2013-02
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Maiti SN;Huls H;Singh H;Dawson M;Figliola M;Olivares S;Rao P;Zhao YJ;Multani A;Yang G;Zhang L;Crossland D;Ang S;Torikai H;Rabinovich B;Lee DA;Kebriaei P;Hackett P;Champlin RE;Cooper LJ
  • 通讯作者:
    Cooper LJ
PD-1 and BTLA and CD8(+) T-cell "exhaustion" in cancer: "Exercising" an alternative viewpoint.
  • DOI:
    10.4161/onci.20823
  • 发表时间:
    2012-08-01
  • 期刊:
  • 影响因子:
    7.2
  • 作者:
    Haymaker C;Wu R;Bernatchez C;Radvanyi L
  • 通讯作者:
    Radvanyi L
Targeting the Leukemia Antigen PR1 with Immunotherapy for the Treatment of Multiple Myeloma.
通过免疫疗法靶向白血病抗原 PR1 来治疗多发性骨髓瘤。
The kinase TBK1 controls IgA class switching by negatively regulating noncanonical NF-κB signaling.
  • DOI:
    10.1038/ni.2423
  • 发表时间:
    2012-11
  • 期刊:
  • 影响因子:
    30.5
  • 作者:
  • 通讯作者:
Human Pentraxins Bind to Misfolded Proteins and Inhibit Production of Type I Interferon Induced by Nucleic Acid-Containing Amyloid.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JAMES P ALLISON其他文献

JAMES P ALLISON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JAMES P ALLISON', 18)}}的其他基金

Integrating Ipilimumab Immunotherapy with Approved Treatment Strategies in CRPC
将 Ipilimumab 免疫疗法与已批准的 CRPC 治疗策略相结合
  • 批准号:
    8999528
  • 财政年份:
    2009
  • 资助金额:
    $ 37.46万
  • 项目类别:
Integrating Ipilimumab Immunotherapy with Approved Treatment Strategies in CRPC
将 Ipilimumab 免疫疗法与已批准的 CRPC 治疗策略相结合
  • 批准号:
    10005150
  • 财政年份:
    2009
  • 资助金额:
    $ 37.46万
  • 项目类别:
CHECKPOINT BLOCKADE IN IMMUNOTHERAPY OF PROSTATE CANCER
前列腺癌免疫治疗中的检查点封锁
  • 批准号:
    7147038
  • 财政年份:
    2005
  • 资助金额:
    $ 37.46万
  • 项目类别:
High Speed Cell Sorter
高速细胞分选仪
  • 批准号:
    6440863
  • 财政年份:
    2002
  • 资助金额:
    $ 37.46万
  • 项目类别:
CHECKPOINT BLOCKADE IN IMMUNOTHERAPY OF PROSTATE CANCER
前列腺癌免疫治疗中的检查点封锁
  • 批准号:
    8555198
  • 财政年份:
    2001
  • 资助金额:
    $ 37.46万
  • 项目类别:
04 Immunology
04 免疫学
  • 批准号:
    10212265
  • 财政年份:
    1996
  • 资助金额:
    $ 37.46万
  • 项目类别:
04 Immunology
04 免疫学
  • 批准号:
    10466998
  • 财政年份:
    1996
  • 资助金额:
    $ 37.46万
  • 项目类别:
04 Immunology
04 免疫学
  • 批准号:
    10655531
  • 财政年份:
    1996
  • 资助金额:
    $ 37.46万
  • 项目类别:
T CELL COSTIMULATION IN ANTITUMOR RESPONSES
T 细胞共刺激在抗肿瘤反应中的作用
  • 批准号:
    6171918
  • 财政年份:
    1992
  • 资助金额:
    $ 37.46万
  • 项目类别:
T CELL COSTIMULATION IN ANTITUMOR RESPONSES
T 细胞共刺激在抗肿瘤反应中的作用
  • 批准号:
    2098691
  • 财政年份:
    1992
  • 资助金额:
    $ 37.46万
  • 项目类别:

相似海外基金

Molecular Epidemiological and pathological studies on the association between lipoprotein(a) and malignant neoplasms
脂蛋白(a)与恶性肿瘤关系的分子流行病学及病理学研究
  • 批准号:
    17K08718
  • 财政年份:
    2017
  • 资助金额:
    $ 37.46万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Integrated analysis and detection of new therapeutic target aimed for improvement of prognosis in the patients with pancreatic malignant neoplasms
综合分析检测改善胰腺恶性肿瘤患者预后的新治疗靶点
  • 批准号:
    24501337
  • 财政年份:
    2012
  • 资助金额:
    $ 37.46万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
GENETIC PREDISPOSITION TO SECOND MALIGNANT NEOPLASMS FOLLOWING CHILDHOOD
儿童期后第二次恶性肿瘤的遗传倾向
  • 批准号:
    6116914
  • 财政年份:
    1998
  • 资助金额:
    $ 37.46万
  • 项目类别:
GENETIC PREDISPOSITION TO SECOND MALIGNANT NEOPLASMS FOLLOWING CHILDHOOD
儿童期后第二次恶性肿瘤的遗传倾向
  • 批准号:
    6219852
  • 财政年份:
    1998
  • 资助金额:
    $ 37.46万
  • 项目类别:
GENETIC PREDISPOSITION TO SECOND MALIGNANT NEOPLASMS FOLLOWING CHILDHOOD
儿童期后第二次恶性肿瘤的遗传倾向
  • 批准号:
    6278109
  • 财政年份:
    1997
  • 资助金额:
    $ 37.46万
  • 项目类别:
SECOND MALIGNANT NEOPLASMS FOLLOWING CANCER OF THE OVARY
卵巢癌后的第二个恶性肿瘤
  • 批准号:
    2305338
  • 财政年份:
    1996
  • 资助金额:
    $ 37.46万
  • 项目类别:
SECOND MALIGNANT NEOPLASMS FOLLOWING CANCER OF THE OVARY
卵巢癌后的第二个恶性肿瘤
  • 批准号:
    2305324
  • 财政年份:
    1996
  • 资助金额:
    $ 37.46万
  • 项目类别:
SECOND MALIGNANT NEOPLASMS FOLLOWING CANCER OF THE OVARY
卵巢癌后的第二个恶性肿瘤
  • 批准号:
    2451660
  • 财政年份:
    1996
  • 资助金额:
    $ 37.46万
  • 项目类别:
SECOND MALIGNANT NEOPLASMS FOLLOWING CANCER OF THE OVARY
卵巢癌后的第二个恶性肿瘤
  • 批准号:
    2451659
  • 财政年份:
    1996
  • 资助金额:
    $ 37.46万
  • 项目类别:
SECOND MALIGNANT NEOPLASMS FOLLOWING CANCER OF THE OVARY
卵巢癌后的第二个恶性肿瘤
  • 批准号:
    2305309
  • 财政年份:
    1995
  • 资助金额:
    $ 37.46万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了